Interleukin Genetics transfers stock trading from NYSE Amex to OTCQB Marketplace

Download PDF Copy

Aug 16 2010

Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that trading of shares of the Company's common stock will be transferred from the NYSE Amex to the OTCQB™ Marketplace effective today, August 16, 2010. Investors in the Company can trade the stock easily in this marketplace, where Interleukin Genetics' symbol will now be ILIU. The OTCQB market tier was recently introduced to better distinguish OTC securities that are registered and fully reporting with the Securities and Exchange Commission (SEC) or a banking or insurance regulator. Investors can now view real time stock quotes for ILIU at http://www.otcmarkets.com.

"Trading on the OTCQB brings a level of market maker transparency, which is good for our shareholders. Our marketplace transfer will enable the Company to stay focused on dedicating resources to partnering and driving continued revenue growth of our Inherent Health brand of genetic tests," said Lewis H. Bender, CEO. "We just announced a significant increase in quarterly revenue and a new major funded partnership. We will continue to pursue additional relationships with companies involved in markets that align with our products."

Source:

Interleukin Genetics, Inc.

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Study shows sharp increase in kidney disease deaths linked to high blood pressure

Understanding how mRNA stability influences immune diseases

Unraveling adult ADHD symptoms through genetics and data science

Breakthrough discovery reveals treatable form of familial mesothelioma

Study finds links between human genetic variation, gut mycobiome, and chronic disease risk

Researchers uncover a promising new therapeutic target for Barth syndrome

Salt substitute use remains low among Americans with high blood pressure

Study uncovers three-way relationships between gut fungi, genetics and disease risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.